Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
Abstract
Abstract In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.
Article Details
Authors (68)
Hrishikesh K. Srinagesh
Stanford University School of Medicine
Vishal Gupta
Amy Zhang
Michael Grunwald
4Division of Leukemia, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC
Matthew Connor
5Division of Hematology and Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
Vamsi K. Kota
16Georgia Cancer Center at Augusta University, Augusta, GA
Jacob Boccucci
7Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA
Matthew Ulrickson
28Banner MD Anderson Cancer Center, Gilbert, AZ
Roshini Pradeep
8Section of Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ
LaQuisa Hill
9Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX
Stephanie B. Tsai
27Loyola University Medical Center, Maywood, IL
Timothy O'Connor
10Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL
Karamjeet Sandhu
11Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA
Anjali S. Advani
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
Ran Reshef
13Division of Hematology/Oncology, Blood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, NY
Christian A. Gordillo
13Division of Hematology/Oncology, Blood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, NY
Marlise R. Luskin
20Dana-Farber Cancer Institute, Boston, MA
Evan C. Chen
15Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA
Chenyu Lin
Department of Earth and Planetary Sciences, Harvard University
Ryan D. Cassaday
8Division of Hematology and Oncology, University of Washington, Seattle, WA
Noam E. Kopmar
17Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Navneet S. Majhail
19Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, HCA Healthcare, Nashville, TN
Minoo Battiwalla
19Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, HCA Healthcare, Nashville, TN
Stephen A. Strickland
32Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN
Catherine J. Lee
13Fred Hutchinson Cancer Center, University of Washington, Seattle, WA
Silvina Odstrcil Bobillo
20Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT
Talal Hilal
13Mayo Clinic, Phoenix, AZ
Jae H. Park
Yannis K. Valtis
22Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Rawan Faramand
24Moffitt Cancer Center and Research Institute, Tampa, FL
Melhem M. Solh
26The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA
Caitlin Guzowski
25Northside Hospital Cancer Institute, Atlanta, GA
Sumithira Vasu
29Department of Internal Medicine, The Ohio State University, Columbus, OH
Jessica T. Leonard
33Division of Hematology Oncology, Oregon Health & Science University, Portland, OR
Virginia Tan
27Knight Cancer Institute, Department of Medical Oncology, Oregon Health and Science University, Portland, OR
Eunice S. Wang
30Roswell Park Cancer Institute, Buffalo, NY
Ross McCauley
28Division of Hematology and Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Joshua Sasine
29Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
Kevin Tang
Katharine Miller
3Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, CA
Katherine C. Sutherland
30Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
Michael Daunov
9University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH
Razan Mohty
32Division of Hematology and Oncology, O’Neal Comprehensive Cancer Center, The University of Alabama, Birmingham, AL
Omer Jamy
15Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL
Muthu V. Kumaran
33Stem Cell Transplantation and Cellular Therapy Program, University of Arkansas Medical Center, Little Rock, AR
Rasmus T. Hoeg
34Division of Malignant Hematology/Cellular Therapy and Transplantation, Department of Internal Medicine, University of California Davis, Sacramento, CA
Kaitlyn C. Dykes
10Division of Blood and Marrow Transplantation, University of California, San Diego, La Jolla, CA
Aaron C. Logan
19Department of Medicine, University of California San Francisco, San Francisco, CA
Tamer Othman
36Hematology, Blood and Marrow Transplantation, and Cellular Therapy Program, University of California San Francisco, San Francisco, CA
Wendy Stock
Marc Schwartz
Kenneth Byrd
39Division of Hematologic Malignancies and Cellular Therapeutics, Department of Medicine, University of Kansas School of Medicine, Kansas City, KS
Fevzi Yalniz
40Division of Hematology and Blood Marrow Transplantation, Department of Medicine, University of Kentucky College of Medicine, Lexington, KY
Veronika Bachanova
Sean Tracy
41Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
George Yaghmour
University of Southern California, Los Angeles, California, United States
Vivian M. Irizarry Gatell
43Division of Hematology/Oncology, University of Texas Southwestern, Dallas, TX
Clayton W. Jackson
43Division of Hematology/Oncology, University of Texas Southwestern, Dallas, TX
Olalekan O. Oluwole
Bhagirathbhai Dholaria
Kristen M. O'Dwyer
21University of Rochester Medical Center, Rochester, NY
Jozal Moore
45Division of Hematology and Oncology, Department of Medicine, Wilmot Cancer Institute of University of Rochester, Rochester, NY
Gregory W. Roloff
3Section of Hematology/Oncology, University of Chicago, Chicago, IL
Noelle V. Frey
Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia
Ibrahim Aldoss
Bijal D. Shah
34Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
Caspian H. Oliai
2Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA
Lori S. Muffly
Stanford University School of Medicine